v3.25.2
Paragon Option Agreements - Narrative (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Apr. 28, 2025
USD ($)
Mar. 18, 2025
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2025
USD ($)
employee
vote
Dec. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2026
Dec. 31, 2025
Asset Acquisition [Line Items]                
Research and development [1]     $ 12,081     $ 22,708    
License Agreement Terms | Paragon Option Agreements                
Asset Acquisition [Line Items]                
Number of employees overseeing and coordinating the project | employee       2        
Paragon Therapeutics | Paragon Option Agreements                
Asset Acquisition [Line Items]                
Accounts payable and other current liabilities     5,200 $ 5,200   5,200    
Paragon Therapeutics | Paragon Option Agreements | Forecast                
Asset Acquisition [Line Items]                
Percent of outstanding shares             1.00% 1.00%
Paragon Therapeutics | License Agreement Terms | Paragon Option Agreements                
Asset Acquisition [Line Items]                
Number of employees overseeing and coordinating the project | employee       2        
Number of votes | vote       1        
Option agreement termination period, maximum contractual period       30 days        
Expiration period       30 days        
Termination period       30 days        
Research and development     $ 5,019     $ 13,033    
Paragon Therapeutics | License Agreement Terms | CR-001 | Paragon Option Agreements                
Asset Acquisition [Line Items]                
Non-refundable milestone payments   $ 22,000            
Milestone payment $ 2,500              
Percent reduction to royalty payment due to invalid patent       30.00%        
Termination period due to breach of contract       60 days        
Sublicense agreement period       30 days        
Paragon Therapeutics | License Agreement Terms | CR-002 | Paragon Option Agreements                
Asset Acquisition [Line Items]                
Non-refundable milestone payments   $ 46,000            
Paragon Therapeutics | License Agreement Terms | CR-003 | Paragon Option Agreements                
Asset Acquisition [Line Items]                
Non-refundable milestone payments $ 46,000              
WuXi Biologics Ireland Limited | Cell Line License Agreement                
Asset Acquisition [Line Items]                
Research and development         $ 150      
Percent of net sales, royalty payment (less than)         1.00%      
Option agreement, termination period           6 months    
Option agreement termination period due to breach of contract           60 days    
Option agreement termination period due to failure to pay           30 days    
[1] Includes related party amount of $6,292 and $15,069 for the three and six months ended June 30, 2025, respectively.